文献速递心力衰竭与心肌病

沙库巴曲缬沙坦在射血分数轻度降低或保留且心衰加重患者中的应用

Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2023-05-21

PARAGLIDE-HF 试验纳入 466 例 EF>40% 且近期心衰加重事件后 30 天内稳定的患者,随机比较沙库巴曲缬沙坦与缬沙坦。结果显示沙库巴曲缬沙坦组 NT-proBNP 时间平均下降幅度更大(变化比 0.85,95%CI 0.73-0.999,P=0.049),但分层复合终点未达显著(win ratio 1.19,95%CI 0.93-1.52,P=0.16)。

要点

  • EF>40% 心衰加重后启用沙库巴曲缬沙坦可更显著降低 NT-proBNP。
  • 分层复合终点无显著改善,但 EF≤60% 亚组显示更大获益。
  • 沙库巴曲缬沙坦减少肾功能恶化但增加症状性低血压。

核心结论

  • 在 EF>40% 且心衰加重后稳定的患者中,沙库巴曲缬沙坦较缬沙坦更显著降低 NT-proBNP,并可能带来临床获益,但症状性低血压更常见。

研究设计与样本

  • PARAGLIDE-HF 为双盲随机对照试验,纳入 EF>40% 且心衰加重事件后 30 天内入组的患者,共 466 例(沙库巴曲缬沙坦 233 例,缬沙坦 233 例)。

主要发现

  • 主要终点 NT-proBNP 从基线至第 4 周和第 8 周的时间平均比例变化:沙库巴曲缬沙坦组下降更大(变化比 0.85,95%CI 0.73-0.999,P=0.049)。
  • 分层复合终点(心血管死亡、心衰住院、紧急心衰就诊、NT-proBNP 变化)有利于沙库巴曲缬沙坦但未达统计学显著(win ratio 1.19,95%CI 0.93-1.52,P=0.16)。
  • 沙库巴曲缬沙坦减少肾功能恶化(OR 0.61,95%CI 0.40-0.93),但增加症状性低血压(OR 1.73,95%CI 1.09-2.76)。
  • EF≤60% 亚组中,沙库巴曲缬沙坦对 NT-proBNP 变化(0.78,95%CI 0.61-0.98)和分层复合终点(win ratio 1.46,95%CI 1.09-1.95)的治疗效应更大。

临床怎么用

  • 对于 EF>40% 且近期心衰加重后稳定的患者,可考虑启用沙库巴曲缬沙坦以降低 NT-proBNP,尤其 EF≤60% 者可能获益更多。
  • 启用沙库巴曲缬沙坦时需监测症状性低血压和肾功能。

局限性

  • 分层复合终点未达统计学显著,临床获益证据有限。
  • 亚组分析结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: U.S. guidelines recommend consideration of sacubitril/valsartan in chronic heart failure (HF) and mildly reduced or preserved ejection fraction (EF). Whether initiation is safe and effective in EF >40% after a worsening heart failure (WHF) event is unknown. OBJECTIVES: PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF) assessed sacubitril/valsartan vs valsartan in EF >40% following a recent WHF event. METHODS: PARAGLIDE-HF is a double-blind, randomized controlled trial of sacubitril/valsartan vs valsartan in patients with EF >40% enrolled within 30 days of a WHF event. The primary endpoint was time-averaged proportional change in amino terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through Weeks 4 and 8. A secondary hierarchical outcome (win ratio) consisted of: 1) cardiovascular death; 2) HF hospitalizations; 3) urgent HF visits; and 4) change in NT-proBNP. RESULTS: In 466 patients (233 sacubitril/valsartan; 233 valsartan), time-averaged reduction in the NT-proBNP was greater with sacubitril/valsartan (ratio of change: 0.85; 95% CI: 0.73-0.999; P = 0.049). The hierarchical outcome favored sacubitril/valsartan but was not significant (unmatched win ratio: 1.19; 95% CI: 0.93-1.52; P = 0.16). Sacubitril/valsartan reduced worsening renal function (OR: 0.61; 95% CI: 0.40-0.93) but increased symptomatic hypotension (OR: 1.73; 95% CI: 1.09-2.76). There was evidence of a larger treatment effect in the subgroup with EF ≤60% for NT-proBNP change (0.78; 95% CI: 0.61-0.98) and the hierarchical outcome (win ratio: 1.46; 95% CI: 1.09-1.95). CONCLUSIONS: Among patients with EF >40% stabilized after WHF, sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared with valsartan alone, despite more symptomatic hypotension. (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF; NCT03988634).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023. PMID: 37212758. doi:10.1016/j.jacc.2023.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。